Clinical Report: FARETINA Study Confirms Faricimab Durability

Overview

The FARETINA study demonstrates that faricimab treatment for neovascular AMD maintains stable vision and anatomical improvement over two years, with reduced treatment burden. The findings are based on a large cohort from the IRIS Registry, reinforcing the efficacy and safety of faricimab in real-world settings.

Background

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, making effective treatment crucial. Faricimab, a bispecific antibody, has shown promise in clinical trials, but real-world data are essential to confirm its durability and safety. The FARETINA study provides insights into the long-term outcomes of faricimab in a diverse patient population.

Data Highlights

Key Findings

• Stable vision was maintained in both treatment-naive and previously treated groups over two years.
• Anatomic improvement was observed in both groups during the study period.
• Patients required fewer injections in the second half of the first year, indicating extended treatment intervals.
• Safety profile was reassuring, with low rates of endophthalmitis (<0.1%) and intraocular inflammation (<0.5%).
• The study included a diverse population, enhancing the applicability of the findings to real-world settings.

Clinical Implications

The findings from the FARETINA study support the use of faricimab as a durable treatment option for neovascular AMD, potentially reducing the treatment burden on patients. Clinicians should consider these real-world outcomes when developing treatment plans for AMD patients.

Conclusion

The FARETINA study reinforces the effectiveness and safety of faricimab for neovascular AMD, highlighting its potential to improve patient outcomes in a real-world context. Continued monitoring and research will be essential to further validate these findings.

References

1. Retinal Physician, Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study, 2024 -- https://www.retinalphysician.com/issues/2024/julyaugust/faricimab-shows-durable-efficacy-and-safety-in-2-year-dme-study
2. Conexiant, Early Fluid Resolution Predicts Faricimab Durability, 2026 -- https://conexiant.com/ophthalmology/articles/early-fluid-resolution-predicts-faricimab-durability/
3. The Ophthalmologist, Early Fluid Resolution Predicts Faricimab Durability, 2026 -- https://www.theophthalmologist.com/issues/2026/articles/april/early-fluid-resolution-predicts-faricimab-durability/
4. Retinal Physician, Video: Faricimab Maintains Long-Term Stability in DME, 2025 -- https://www.retinalphysician.com/issues/2025/julyaugust/asrs12
5. Diabetic Retinopathy Preferred Practice Pattern® - PubMed, 2025 -- https://pubmed.ncbi.nlm.nih.gov/39918521/?utm_source=openai
6. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials - PubMed, 2025 -- https://pubmed.ncbi.nlm.nih.gov/38158159/?utm_source=openai
7. Comparative efficacy and safety of faricimab, aflibercept, conbercept, and ranibizumab for neovascular age-related macular degeneration: A systematic review and network meta-analysis - ScienceDirect, 2025 -- https://www.sciencedirect.com/science/article/pii/S0014299925011604
8. Retinal Physician — Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study
9. conexiant — Early Fluid Resolution Predicts Faricimab Durability
10. the ophthalmologist — Early Fluid Resolution Predicts Faricimab Durability
11. retinal physician — Video: Faricimab Maintains Long-Term Stability in DME
12. Diabetic Retinopathy Preferred Practice Pattern® - PubMed
13. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials - PubMed
14. Comparative efficacy and safety of faricimab, aflibercept, conbercept, and ranibizumab for neovascular age-related macular degeneration: A systematic review and network meta-analysis - ScienceDirect